Silexion Therapeutics (SLXN) shares rose more than 100% in recent Tuesday trading after the company reported "promising" preclinical data from its tumor drug candidate, SIL-204, in mice.
Based on the data, the company said the drug candidate administered in an extended-release formulation reduced tumor growth by more than 50% after 30 days, with about 50% of tumors showing complete necrosis in human pancreatic tumors.
The company also said that the drug candidate administered subcutaneously inhibited tumor growth in mouse metastatic pancreatic orthotopic models.
"While the current data shows robust tumor growth inhibition, further studies aim to evaluate its impact on metastases, which the Company is cautiously optimistic about," the company said.
Silexion said it is actively exploring how the data may be used to determine an expanded treatment strategy for certain cancers and expects to announce the details of its expanded development plan "shortly."
Price: 1.16, Change: +0.58, Percent Change: +100.17
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.